dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Camidge, D. Ross |
dc.contributor.author | Ahn, Myung-Ju |
dc.contributor.author | Yang, James C. H. |
dc.contributor.author | Han, Ji-Youn |
dc.contributor.author | Hochmair, Maximilian J. |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Kim, Hye Ryun |
dc.date.accessioned | 2021-09-23T11:08:10Z |
dc.date.available | 2021-09-23T11:08:10Z |
dc.date.issued | 2020-11-01 |
dc.identifier.citation | Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592–603. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/6346 |
dc.description | Cáncer de pulmón; Brigatinib; Estudio ALTA-1L |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;38(31) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic - Eficàcia |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.20.00505 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.1200/JCO.20.00505 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Camidge DR] University of Colorado Cancer Center, Aurora, CO. [Kim HR] Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. [Ahn MJ] Samsung Medical Center, Seoul, South Korea. [Yang JCH] National Taiwan University Hospital, Taipei, Taiwan. [Han JY] National Cancer Center, Goyang, South Korea. [Hochmair MJ] Department of Respiratory and Critical Care Medicine, Krankenhaus Nord–Klinik Floridsdorf, Vienna, Austria. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 32780660 |
dc.identifier.wos | 000588411100004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |